Photo: Anne Kohola
In her doctoral dissertation, Licentiate of Medicine Anna Alexanova developed and applied a patient-specific stem cell-based liver cell model to investigate the molecular mechanisms underlying coronary artery disease. Using integrated lipidomic, proteomic and microRNA analyses, the study identified distinct hepatic molecular signatures associated with stable and acute forms of coronary artery disease. The findings suggest that disease-related differences are intrinsic to patients and likely reflect underlying genetic variation. The results demonstrate that patient-derived stem cell-based liver cells can serve as a useful platform for studying molecular features associated with coronary artery disease. The study also highlights the value of integrating multiple omics approaches to characterize complex cardiometabolic diseases and supports the use of this platform for functional studies of disease-associated genetic variation.
The doctoral dissertation Hepatic Molecular Signatures in Coronary Artery Disease: Multi-Omics Analysis of Lipid Metabolism in iPSC-Derived Hepatocyte-Like Cells by Licentiate of Medicine Anna Alexanova will be publicly examined in the Faculty of Medicine and Health Technology at Tampere University on 27 November 2026. The dissertation is in the field of cardiovascular research.
The Opponent will be Professor Jan Borén from the University of Gothenburg, Sweden. The Custos will be Professor Katriina Aalto-Setälä from the Faculty of Medicine and Health Technology, Tampere University.